ArticleFrontiers in endocrinology2025
Loss of the PDLIM2 protein during chronic colitis promotes inflammation, impaired epithelium recovery, alterations to the microbiome and oxidative stress.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ulcerative colitis (UC) involves impaired wound healing processes contributing to sustained immune and microbial interactions that aggravate intestinal injury and may progress to colitis-associated cancer (CAC). Here we investigated whether PDLIM2, a known regulator of both epithelial and immune cell fate, contributes to colitis progression. Methods: PDLIM2 knockout mice (-/-) and wildtype littermates (+/+) were assessed for responses to dextran sodium sulphate (DSS)-induced colitis, and to aoxymethane +DSS. Microbiota were assessed using 16s rRNA amplicon sequencing. Mechanistic studies were carried out in Caco-2 cell cultures, and in silico analysis was carried out on single cell RNA sequencing data from patients with Ulcerative colitis or Crohn's disease. Results and discussion: Compared to PDLIM2 +/+ mice, PDLIM2 -/- mice exhibited exacerbated and unresolved epithelial damage and inflammation accompanied by immune cell infiltration, which was precluded sufficient time to observe tunour development. PDLIM2 -/- mice exhibited altered basal gut microbial diversity, composition and predicted functionality compared to +/+ mice. Interestingly, in +/+ mice, PDLIM2 expression was lost over the course of DSS-induced colitis. Mechanistic studies in Caco-2 enterocyte cell cultures demonstrated that PDLIM2 suppression resulted in impaired cell adhesion signalling and sustained oxidative stress. In silico analysis of single cell RNA seq data sets from patients with ulcerative colitis and Crohn's disease demonstrated that although PDLIM2 was clearly expressed in normal human colonic epithelial enterocyte populations, its expression declined in both ulcerative colitis and Crohn's disease. We conclude that PDLIM2 is necessary for intestinal homeostasis through regulation of cell adhesion and antioxidant pathways, while loss of PDLIM2 sustains inflammation and epithelial damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.